[1]朱婧 蒋晓红 项守奎 许晨 华飞.1型糖尿病患者尿酸水平与血脂异常的 相关性研究[J].国际内分泌代谢杂志,2020,40(01):16-20.[doi:10.3760/cma.j.issn.1673-4157.2020.01.004]
　Zhu Jing,Jiang Xiaohong,Xiang Shoukui,et al.Correlation between uric acid level and dyslipidemia in patients with type 1 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2020,40(01):16-20.[doi:10.3760/cma.j.issn.1673-4157.2020.01.004]
点击复制

1型糖尿病患者尿酸水平与血脂异常的 相关性研究()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
40
期数:
2020年01期
页码:
16-20
栏目:
论著
出版日期:
2020-01-20

文章信息/Info

Title:
Correlation between uric acid level and dyslipidemia in patients with type 1 diabetes mellitus
作者:
朱婧 蒋晓红 项守奎 许晨 华飞
苏州大学附属第三医院内分泌代谢科,常州 213003
Author(s):
Zhu Jing;  Jiang Xiaohong;  Xiang Shoukui;  Xu Chen;  Hua Fei
Department of Endocrinology and Metabolism, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China
关键词:
1型糖尿病;  血脂异常;  尿酸
Keywords:
Type 1 diabetes mellitus;  Dyslipidemia;  Uric acid
DOI:
10.3760/cma.j.issn.1673-4157.2020.01.004
摘要:
目的 探究1型糖尿病(T1DM)患者的血脂特点及尿酸水平与血脂异常的相关性。方法 选取2015年6月至2019年2月于苏州大学附属第三医院内分泌代谢科住院的T1DM患者201例,作为T1DM组。选取健康体检中心的非糖尿病健康人136名,作为健康对照组。前者按照2016版中国成人血脂异常防治指南诊断标准分为血脂异常T1DM组和血脂正常T1DM组。收集年龄、身高、体重、血压、肝肾功能、尿酸、空腹血糖、HbA1c、甲状腺功能、总胆固醇、甘油三酯、高密度脂蛋白-胆固醇(HDL-C)、低密度脂蛋白-胆固醇(LDL-C)等临床生化指标进行比较。采用Spearman相关性分析探究尿酸水平与生化指标的相关性。二元logistic回归分析T1DM血脂异常的影响因素。结果 T1DM组血脂异常总体发生率为24.9%(50/201),主要为低HDL-C血症、高甘油三酯血症和高LDL-C血症,发生率分别为18.9%(38/201)、5.5%(11/201)和2.0%(4/201)。与健康对照组相比,T1DM组收缩压、舒张压、空腹血糖、HbA1c、甘油三酯、LDL-C水平升高(t=2.105～26.048,P均<0.05),体重指数、HDL-C、FT3水平降低(t=-12.660～-4.253,P均<0.05)。与血脂正常T1DM组相比,血脂异常T1DM组尿酸、HbA1c、空腹C肽、舒张压水平均升高(t=2.283～3.193,P均<0.05),年龄降低(t=-2.300, P=0.023)。T1DM患者尿酸水平与甘油三酯呈正相关(r=0.199, P<0.05),与HDL-C、年龄呈负相关(r=-0.163、-0.319, P均<0.05)。Logistic回归分析显示,尿酸(OR=1.007, 95% CI: 1.002～1.011, P=0.002)、舒张压(OR=1.064, 95% CI: 1.015～1.116, P=0.010)、HbA1c(OR=1.197,95% CI: 1.027～1.394, P=0.021)是T1DM发生血脂异常的独立危险因素。结论 T1DM患者存在血脂异常,尿酸水平可能与T1DM患者血脂异常相关。
Abstract:
Objective To investigate the clinical characteristics of dyslipidemia as well as relationship between serum uric acid levels and dyslipidemia in patients with type 1 diabetes mellitus(T1DM).Methods From June 2015 to February 2019, a total of 201 patients with T1DM from the Department of Endocrinology and Metabolism, The Third Affiliated Hospital of Soochow University were enrolled as T1DM group, and 136 healthy individuals in health examination center were enrolled as healthy control group. T1DM group was subdivided into T1DM with abnormal blood lipids group and T1DM with normal blood lipids group according to the diagnostic criteria by the Guideline for Prevention and Treatment of Dyslipidemia in Adults in China(2016 Version). Data including age, height, weight, blood pressure, hepatic and renal function, uric acid, fasting glucose, HbA1c, thyroid function, total cholesterol, triglyceride, high-density lipoprotein cholesterol(HDL-C), and low-density lipoprotein cholesterol(LDL-C)were collected. Spearman correlation analysis was used to explore the association between uric acid and other laboratory markers. Binary logistic regression analysis was used to analyze the risk factors of T1DM with dyslipidemia.Results The overall incidence of dyslipidemia in T1DM group was 24.9%(50/201). The highest incidence were observed for low HDL-C level, hypertriglyceridemia, and high LDL-C level, their incidences were 18.9%(38/201), 5.5%(11/201)and 2.0%(4/201)respectively. Compared with healthy control group, the systolic blood pressure, diastolic blood pressure, fasting glucose, HbA1c, triglyceride and LDL-C levels were increased(t=2.105-26.048, all P<0.05), whereas the body mass index, HDL-C, and FT3 were decreased(t=-12.660--4.253, all P<0.05)in T1DM group. Compared with T1DM with normal blood lipids group, the levels of uric acid, HbA1c, fasting C peptide and diastolic blood pressure were increased(t=2.283-3.193,all P<0.05), while the age was decreased(t=-2.300, P=0.023)in T1DM with abnormal blood lipids group. The uric acid level was positively correlated with triglyceride(r=0.199, P<0.05), and negatively associated with HDL-C and age(r=-0.163, -0.319, all P<0.05)in patients with T1DM. The logistic regression analysis showed that uric acid(OR=1.007, 95% CI: 1.002-1.011, P=0.002), diastolic blood pressure(OR=1.064,95% CI:1.015-1.116, P=0.010)and HbA1c(OR=1.197, 95% CI: 1.027-1.394, P=0.021)were independent risk factors of dyslipidemia in patients with T1DM.Conclusion Patients with T1DM have dyslipidemia, and the uric acid level may associate with dyslipidemia in patients with T1DM.

参考文献/References:

[1] 翁建平.关于我国1型糖尿病的几点线索[J].中华医学信息导报, 2017, 32(11): 12. DOI:10.3969/cma.j.issn.1000-8039.2017.11.011.
[2] Atkinson MA,Eisenbarth GS,Michels AW.Type 1 diabetes[J].Lancet,2014,383(9911):69-82.DOI:10.1016/S0140-6736(13)60591-7.
[3] Bjornstad P,Donaghue KC,Maahs DM.Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?[J].Lancet Diabetes Endocrinol,2018,6(10):809-820.DOI:10.1016/S2213-8587(18)30035-4.
[4] Kanbay M,Yilmaz MI,Sonmez A,et al.Serum uric acid independently predicts cardiovascular events in advanced nephropathy[J].Am J Nephrol,2012,36(4):324-331.DOI:10.1159/000342390.
[5] Maahs DM,Caramori L,Cherney DZ,et al.Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss(PERL)allopurinol study[J].Curr Diab Rep,2013,13(4):550-559.DOI:10.1007/s11892-013-0381-0.
[6] Redondo MJ,Foster NC,Libman IM,et al.Prevalence of cardiovascular risk factors in youth with type 1 diabetes and elevated body mass index[J].Acta Diabetol,2016,53(2):271-277.DOI:10.1007/s00592-015-0785-1.
[7] Bulut T,Demirel F,Metin A.The prevalence of dyslipidemia and associated factors in children and adolescents with type 1 diabetes[J].J Pediatr Endocrinol Metab,2017,30(2):181-187.DOI:10.1515/jpem-2016-0111.
[8] Pérez A,Wägner AM,Carreras G,et al.Prevalence and phenotypic distribution of dyslipidemia in type 1 diabetes mellitus: effect of glycemic control[J].Arch Intern Med,2000,160(18):2756-2762.DOI:10.1001/archinte.160.18.2756.
[9] Libby P,Nathan DM,Abraham K,et al.Report of the national heart, lung, and blood institute-national institute of diabetes and digestive and kidney diseases working group on cardiovascular complications of type 1 diabetes mellitus[J].Circulation,2005,111(25):3489-3493.DOI:10.1161/CIRCULATIONAHA.104.529651.
[10] Li Y,Zhao D,Li Y,et al.Serum C-peptide as a key contributor to lipid-related residual cardiovascular risk in the elderly[J].Arch Gerontol Geriatr,2017,73:263-268.DOI:10.1016/j.archger.2017.05.018.
[11] Yosten GL,Kolar GR,Redlinger LJ,et al.Evidence for an interaction between proinsulin C-peptide and GPR146[J].J Endocrinol,2013,218(2):B1-B8.DOI:10.1530/JOE-13-0203.
[12] Yu H,Rimbert A,Palmer AE,et al.GPR146 deficiency protects against hypercholesterolemia and atherosclerosis[J].Cell,2019,179(6):1276-1288.e14.DOI:10.1016/j.cell.2019.10.034.
[13] Peng TC,Wang CC,Kao TW,et al.Relationship between hyperuricemia and lipid profiles in US adults[J].Biomed Res Int,2015,2015:127596.DOI:10.1155/2015/127596.
[14] Rodrigues TC,Maahs DM,Johnson RJ,et al. Serum uric acid predicts progression of subclinical coronary atherosclerosis in individuals without renal disease[J].Diabetes Care,2010,33(11):2471-2473.DOI:10.2337/dc10-1007.
[15] Lu W,Xu Y,Shao X,et al.Uric acid produces an inflammatory response through activation of NF-κB in the hypothalamus: implications for the pathogenesis of metabolic disorders[J].Sci Rep,2015,5:12144.DOI:10.1038/srep12144.
[16] Baldwin W,McRae S,Marek G,et al.Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome[J].Diabetes,2011,60(4):1258-1269.DOI:10.2337/db10-0916.
[17] 赵兰江,赵冬.尿酸代谢异常与甘油三酯代谢异常的关系 [J].中华流行病学杂志, 2006,27(4):362-365.DOI:10.3760/j.issn.0254-6450.2006.04.020.
[18] Ansell BJ.Evidence for a combined approach to the management of hypertension and dyslipidemia[J].Am J Hypertens,2005,18(9 Pt 1):1249-1257. DOI:10.1016/j.amjhyper.2005.03.740.
[19] Shah AS,Maahs DM,Stafford JM,et al. Predictors of dyslipidemia over time in youth with type 1 diabetes: for the SEARCH for diabetes in youth study[J].Diabetes Care,2017,40(4):607-613.DOI:10.2337/dc16-2193.
[20] Stettler C,Allemann S,Jüni P,et al.Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials[J].Am Heart J,2006,152(1):27-38.DOI:10.1016/j.ahj.2005.09.015.

相似文献/References:

[1]袁扬,孙子林.PANDER与β细胞凋亡[J].国际内分泌代谢杂志,2007,(04):253.
[2]刘媛 刘超.1型糖尿病青少年儿童心理行为问题研究进展[J].国际内分泌代谢杂志,2015,(01):63.[doi:10.3760/cma.j.issn.1673-4157.2015.01.016]
　Liu Yuan,Liu Chao..Psychological problems in adolescents and children with type 1 diabetes[J].International Journal of Endocrinology and Metabolism,2015,(01):63.[doi:10.3760/cma.j.issn.1673-4157.2015.01.016]
[3]王思倩,吴锦丹.肠促胰素对1型糖尿病患者血糖及胰岛功能的影响[J].国际内分泌代谢杂志,2015,(03):196.[doi:10.3760/cma.j.issn.1673-4157.2015.03.015]
　Wang Siqian,Wu Jindan..Effects of incretin on blood glucose and islet function in type 1 diabetic patients[J].International Journal of Endocrinology and Metabolism,2015,(01):196.[doi:10.3760/cma.j.issn.1673-4157.2015.03.015]
[4]李亚兰,项洁,卜瑞芳.1型糖尿病的DiaPep277免疫治疗[J].国际内分泌代谢杂志,2014,(03):169.[doi:10.3760/cma.j.issn.1673-4157.2014.03.007]
　Li Yalan,Xiang Jie,Bu Ruifang..Immunotherapy with DiaPep277 peptide in type 1 diabetes[J].International Journal of Endocrinology and Metabolism,2014,(01):169.[doi:10.3760/cma.j.issn.1673-4157.2014.03.007]
[5]陈晔,李艳玲,王坚.天然免疫细胞在1型糖尿病中的作用[J].国际内分泌代谢杂志,2014,(03):184.[doi:10.3760/cma.j.issn.1673-4157.2014.03.011]
　Chen Ye,Li Yanling,Wang Jian..Role of innate immune cells in type 1 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2014,(01):184.[doi:10.3760/cma.j.issn.1673-4157.2014.03.011]
[6]蔡芸莹 苏恒.1型糖尿病的非胰岛素治疗[J].国际内分泌代谢杂志,2015,(06):388.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.06.007]
　Cai Yunying,Su Heng.Noninsulin management in type 1 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(01):388.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.06.007]
[7]李依依,韩颖,田秀标,等.天津市糖尿病高危人群血脂异常患病率 及相关危险因素分析[J].国际内分泌代谢杂志,2016,36(03):166.[doi:10.3760/cma.j.issn.1673-4157.2016.03.06]
　Li Yiyi*,Han Ying,Tian Xiubiao,et al.The prevalence and risk factors of dyslipidemia in high-risk population of diabetes in Tianjin[J].International Journal of Endocrinology and Metabolism,2016,36(01):166.[doi:10.3760/cma.j.issn.1673-4157.2016.03.06]
[8]王静 张梅.胰高血糖素在1型糖尿病治疗中的研究进展[J].国际内分泌代谢杂志,2018,38(01):19.[doi:10.3760/cma.j.issn.1673-4157.2018.01.005]
　Wang Jing,Zhang Mei.Research progress of glucagon for the treatment of type 1 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2018,38(01):19.[doi:10.3760/cma.j.issn.1673-4157.2018.01.005]
[9]周小海,安晔,王小玲,等.1型糖尿病合并非酒精性脂肪性肝病与慢性肾脏病的关系[J].国际内分泌代谢杂志,2021,41(04):339.[doi:10.3760/cma.j.cn121383-20200713-07032]
　Zhou Xiaohai,An Ye,Wang Xiaoling,et al.Relationship between nonalcoholic fatty liver disease and chronic kidney disease in patients with type 1 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2021,41(01):339.[doi:10.3760/cma.j.cn121383-20200713-07032]
[10]陈双,杨涛,顾愹.1型糖尿病的诊断与免疫治疗[J].国际内分泌代谢杂志,2021,41(06):578.[doi:10.3760/cma.j.cn121383-20210915-09046]
　Chen Shuang,Yang Tao,Gu Yong..Diagnosis and immunotherapy of type 1 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2021,41(01):578.[doi:10.3760/cma.j.cn121383-20210915-09046]

备注/Memo

备注/Memo:
通信作者:华飞,Email:czhuafei@vip.sina.com
基金项目:常州市卫生人才培养工程资助(2016ZCLJ020); 常州市卫计委重大科技项目(ZD201512)
Corresponding author: Hua Fei, Email:czhuafei@vip.sina.com
Fund program:Changzhou High-level Medical Talents Training Project(2016ZCLJ020); Major Science and Technology Projects of Changzhou Health and Family Planning Commision(ZD201512)
更新日期/Last Update: 2020-01-20